The global market for drugs used in mental disorders was $70.1 billion in 2012 and $68.9 billion in 2013. This market is expected to rise at a compound annual growth rate (CAGR) of 2.3% from 2013 to 2018 and reach $77.1 billion by 2018.
This report provides:
Download Report Overview
SCOPE OF THE STUDY
The scope of this study encompasses psychiatric drugs in pharmaceutical markets. BCC Research analyzes each market and its applications, regulatory environment, technology, market projections and market shares. Technological issues include the latest trends and developments. The emerging market for enzyme inhibitors includes countries like India, China, Japan, Korea, Taiwan, Canada, Africa, Australia, New Zealand, etc.
ABOUT THE AUTHOR
A team of professionals in the biotechnology industry carried out this study. The project manager was Shalini S. Dewan, who holds a master’s degree in pharmaceutical chemistry and has over 14 years of industry experience. Among the research topics she has covered are studies on compounds of potential pharmaceutical interest from ibuprofen and 2-naphthyl acetic acid. Shalini was awarded a Gold Medal by the Prime Minister of India for her work and has worked with top companies in India and in the U.S.
Some of her other reports with BCC Research are:
The lead consultant for this project was Dr. Kapil A. Setia, who holds a doctoral degree in life sciences. She has a number of research publications in her credit, including her thesis, which was given an award of excellence.
PHM074A - January 2011